leadf
logo-loader
viewSkinBioTherapeutics PLC

Successor sought to build £500mln company at SkinBioTherapeutics

Dr Cath O'Neill, CEO of  SkinBioTherapeutics PLC (LON:SBTX), says her successor will have the skills to take the company to commercialisation.
The boss, who invented the skin care technology and the SkinBiotix repair and protect cream, tells Proactive London "it's now the job of someone else with a different skillset to build the business into a £500mln company."
O'Neill has been with life sciences company since the beginning and is looking to return to her scientific roots.

Quick facts: SkinBioTherapeutics PLC

Price: 19.5 GBX

AIM:SBTX
Market: AIM
Market Cap: £24.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

SkinBioTherapeutics CEO hails 'significant scientific milestone' with...

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive's Andrew Scott soon after updating investors on the progress of its cosmetic skincare programme and plans for a psoriasis food supplement trial. Sederma, its partner in the cosmetics programme and a division of Croda...

on 3/8/20

2 min read